OncoDNA, the genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases, will customize its interpretation platform OncoKDM to make it compatible with SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform. The combined offering will enable the analysis and automatic translation of complex genomic data obtained via SOPHiA DDM™ into actionable recommendations, empowering customers to generate tumor genomic profiling insights and produce individual reports.
Based in Lausanne, SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospitals, laboratories and biopharma institutions globally. Listed on the Nasdaq since July, the company had raised $77 million in early 2019. Its investors include the Generation Investment Management, chaired by former US vice president Al Gore, the French company Idinvest, as well as Alychlo, the investment company of Marc Coucke, which has become the largest shareholder over time.
The two companies, which are the leading European players in profiling tests and data interpretation for the treatment of advanced cancers, did not disclose any financial amounts related to this agreement. Their partnership is not exclusive, as both OncoDNA andSOPHiA GENETICS may continue to sell their respective platforms to other customers.
This is the first agreement of this type for OncoDNA, which, on the other hand, has forged several other research and development partnerships with other players such as the Flemish company MyNEO or the Jules Bordet Institute. The BioPark company, which raised 19 million in February 2020 to finance its international expansion, is therefore continuing its expansion by multiplying alliances. In July 2020, it announced the acquisition of the French company IntegraGen, specializing in DNA sequencing. A merger that today allows OncoDNA to now have some 120 employees and to post a turnover of around 15 millions €, growing by 20 to 30% each year.
Have questions or thoughts on this topic?
Want to boost your project? Book a meeting to benefit from our part-time CFO services!
beLean.net is a CFO-as-a-Service offering long-term support in strategy, finance and management for entrepreneurs and investors active in Life Science & Technology.
We are the Walloon reference accelerator in the field of health biotechnology and medical technologies active in Europe. Our mission as part-time CFO is to support our clients to free them up time so that they can focus on their core business.
Contact us to get more information: